QHCY can significantly alleviate clinical symptoms of DSS-induced chronic colitis in mice, protect the function of intestinal mucosal barrier, and improve intestinal microflora by i) inhibiting the expression of TNF-α, IL-6, and IL-1β inflammatory mediators, ii) maintaining the expression of tight junction protein occludin, ZO-1, and MUC2, and iii) improving the diversity of intestinal microflora and regulating the structure and composition of intestinal microflora in mice with chronic colitis. Here, MUC2 is linked to Chronic colitis.